Q&A column, 3/17

Create PDF

1. Kurman RJ, Carcangiu ML, Herrington CS, Young RH, eds. WHO Classification of Tumours of Female Reproductive Organs, 4th ed. Lyon, France: IARC; 2014.
2. Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol. 2006;30(2):230–236.
3. Meserve EE, Brouwer J, Crum CP. Serous tubal intraepithelial neoplasia: the concept and its application [published online ahead of print Jan. 20, 2017]. Mod Pathol. doi:10.1038/modpathol.2016.238.
4. Semmel DR, Folkins AK, Hirsch MS, Nucci MR, Crum CP. Intercepting early pelvic serous carcinoma by routine pathological examination of the fimbria. Mod Pathol. 2009;22(8):985–988.
5. American College of Obstetricians and Gynecologists. Committee opinion: salpingectomy for ovarian cancer prevention. www.bit.ly/acog-ovcancer. Published January 2015.
6. Vang R, Visvanathan K, Gross A, et al. Validation of an algorithm for the diagnosis of serous tubal intraepithelial carcinoma. Int J Gynecol Pathol. 2012;31(3):243–253.
7. College of American Pathologists. Protocol for the examination of specimens from patients with carcinoma of the fallopian tube. www.j.mp/CAP-falltube. Published August 2015.
8. Society of Gynecologic Oncology. SGO clinical practice statement: salpingectomy for ovarian cancer prevention. www.bit.ly/SGO-ovcancer. Published November 2013.

Ekene Okoye, MD, Assistant Professor, Department of Pathology and Genomic Medicine, Weill Cornell Medical College, Houston (Tex.) Methodist Hospital

Dr. Kiechle is a consultant, clinical pathology, Cooper City, Fla. Use the reader service card to submit your inquiries, or address them to Sherrie Rice, CAP TODAY, 325 Wau­ke­gan Road, Northfield, IL 60093; srice@cap.org. Those questions that are of general interest will be answered.